Clinical Trials Directory

Trials / Completed

CompletedNCT01735097

Effect of Nigella Sativa in the Treatment of Palmer Arsenical Keratosis

A Double-blind, Randomized, Placebo-controlled Trial of Nigella Sativa in the Treatment of Palmer Arsenical Keratosis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Daily intake of Nigella sativa for 12 weeks is effective in the treatment of palmer arsenical keratosis

Detailed description

Depending on inclusion and exclusion criteria total 40 patients of palmer arsenical keratosis patients (both male and female; age range 18- 60 years) will be recruited from an arsenic affected area. Study population will be divided randomly into two equal groups: one group will receive vitamin E capsules (200 mg) plus placebo and another group will receive vitamin E capsule plus N. sativa capsules (500 mg) twice daily for 12 weeks. Drinking water (50 mL) and urine (50 mL) samples will be collected before starting the study and estimate the amount of total arsenic in order to confirm the diagnosis. Nail (approx. 1 g) and blood (5 mL) samples will be collected both before and completion of the study to see the efficacy and safety of the drug. Clinical examinations will be done at regular interval (two weeks). Clinical features and adverse effects will be recorded using a structured data collection sheet. Plasma cholesterol, vitamin E, and total antioxidant, serum transaminase, billirubin, creatinine levels and arsenic level in nail will be measured to evaluate the effectiveness of N. sativa on palmer arsenical keratosis patients

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTVitamin EVitamin E (200 mg, soft capsule)
DIETARY_SUPPLEMENTNigella sativaNigella sativa (200 mg, soft capsule)
DIETARY_SUPPLEMENTPlaceboPlacebo (refined oil in soft capsule with same color and size like that contains N. sativa)

Timeline

Start date
2013-01-01
Primary completion
2013-11-01
Completion
2013-11-01
First posted
2012-11-28
Last updated
2014-05-05

Locations

1 site across 1 country: Bangladesh

Source: ClinicalTrials.gov record NCT01735097. Inclusion in this directory is not an endorsement.